HEALTHRAGEOUS AND BOEHRINGER INGELHEIM TO COLLABORATE ON A DIGITAL DIABETES SELF-MANAGEMENT PROGRAM

HEALTHRAGEOUS AND BOEHRINGER INGELHEIM TO COLLABORATE ON A DIGITAL DIABETES SELF-MANAGEMENT PROGRAM

BOSTON, MA, JULY 10, 2012 -- Healthrageous, Inc., a digital health management company, announced today that the company is collaborating with Boehringer Ingelheim to evaluate a lifestyle behavior modification program to improve the health status of people with Type 2 diabetes. Study participants will experience a digital technology intervention combining digital coaching and a wireless glucose meter. The study will evaluate the impact of the intervention on changes in lifestyle behaviors, glucose control, additional medical parameters and medication adherence.

The goal of the program is to leverage technology in a way that makes the personalized journey of self-managing diabetes easier and more effective. During the collaboration, adults employed by a self-insured employer in the U.S., and diagnosed with Type 2 diabetes for at least six months, will have access to Healthrageous’ digital diabetes self-management program. The web and smartphone delivered program will include a personalized action plan with health behavior improvement goals, biometric feedback to demonstrate goal achievement and milestones, digital coach interaction, recognition and incentives for progress, supply and strip refill ordering, capturing HEDIS measures, medication reminders, and social networking support. Further details of the agreement were not provided.

“Innovations in machine learning and technology offer the opportunity to create and deliver a unique experience for each person with Type 2 diabetes,” said Rick Lee, President and CEO, Healthrageous. “Our digital diabetes platform will help us to better understand what motivates individuals to become and remain engaged in self-managing their health. We are delighted to be working with Boehringer Ingelheim on this first-of-its-kind evaluation of the promise that digital technology holds in stemming the Type 2 diabetes epidemic.”

About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.For more information, go to www.boehringer-ingelheim.com.

About Healthrageous
Healthrageous, Inc., is a digital health engagement and management company that supports individual journeys to prevent and self-manage chronic health conditions via the web and a mobile app. It achieves superior engagement through its proprietary platform that incorporates personalized goal setting, health journey maps with gaming dynamics, timely biometric feedback and interactive digital coaching. The digital coach leverages multiple tools such as inspirational messages, recognition and incentives, challenges, social networking, trackers and reminders, and interactive educational content. Healthrageous is headquartered in Boston, MA, and its investors include North Bridge Venture Partners (Boston, MA/San Mateo, CA), Egan Managed Capital (Boston, MA) and Long River Ventures (Amherst, MA). For more information, go to www.healthrageous.com.